Online Investor Kit

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain
-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Application (MAA) expected in November 2020 -- PARSIPPANY, N.J. , Sept.
Toggle Summary IPG and Pacira BioSciences Announce Collaboration to Reduce Postsurgical Opioid Prescribing and Surgical Procedure Costs
ALPHARETTA, Ga. and PARSIPPANY, N.J. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX), a leading provider of non-opioid pain management options, today announced a collaboration to reduce
Toggle Summary Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference
PARSIPPANY, N.J. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 H.C. Wainwright 22 nd Annual Global Investment Conference at 3:30 PM ET on Monday, September 14, 2020 . Live audio of the virtual event can be accessed by
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales of $36.9 Million for August 2020
-- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 -- PARSIPPANY, N.J. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net
Toggle Summary Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options,
Toggle Summary Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
PARSIPPANY, N.J. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 9:10 AM ET on Tuesday, August 11, 2020 . Live audio of the virtual event can be accessed by visiting the
Toggle Summary Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery – PARSIPPANY, N.J. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL®
Toggle Summary Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over PARSIPPANY, N.J. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S.
Toggle Summary Pacira to Report Second Quarter 2020 Financial Results on Thursday August 6, 2020
PARSIPPANY, N.J. , July 30, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020 . Following the release, the company will host a live conference call
Toggle Summary Pacira BioSciences Announces Settlement of Government Investigation
Pacira to Pay $3.5 Million to Settle Various Claims with No Admission of Wrongdoing PARSIPPANY, N.J. , July 28, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced settlement agreements that resolve